PortalPublikationenCytoreductive Surgery for Pancreatic Cancer Improves Overall...

Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy

Standard

Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. / Bahra, Marcus; Pratschke, Johann; Klein, Fritz; Neuhaus, Peter; Boas-Knoop, Sabine; Puhl, Gero; Denecke, Timm; Pullankavumkal, Joyce R; Sinn, Marianne; Riess, Hanno; Pelzer, Uwe.

in: PANCREAS, Jahrgang 44, Nr. 6, 08.2015, S. 930-6.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bahra, M, Pratschke, J, Klein, F, Neuhaus, P, Boas-Knoop, S, Puhl, G, Denecke, T, Pullankavumkal, JR, Sinn, M, Riess, H & Pelzer, U 2015, 'Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy', PANCREAS, Jg. 44, Nr. 6, S. 930-6. https://doi.org/10.1097/MPA.0000000000000365

APA

Bahra, M., Pratschke, J., Klein, F., Neuhaus, P., Boas-Knoop, S., Puhl, G., Denecke, T., Pullankavumkal, J. R., Sinn, M., Riess, H., & Pelzer, U. (2015). Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. PANCREAS, 44(6), 930-6. https://doi.org/10.1097/MPA.0000000000000365

Vancouver

Bahra M, Pratschke J, Klein F, Neuhaus P, Boas-Knoop S, Puhl G et al. Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. PANCREAS. 2015 Aug;44(6):930-6. https://doi.org/10.1097/MPA.0000000000000365

Bibtex

@article{9430e9f918b14c3d89e566cfc6908a4c,
title = "Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy",
abstract = "OBJECTIVES: Pancreatoduodenectomy is feasible also in patients with locally advanced pancreatic adenocarcinoma (PA) nowadays. Data on risk and survival analysis of palliative pancreatic resections followed by gemcitabine-based chemotherapy (Cx) are limited.METHODS: Between 2000 and 2009, a total of 45 patients had primary cytoreductive surgery (cS) (pancreaticoduodenectomy or total pancreatectomy) followed by gemcitabine-based Cx (cS + Cx) for advanced PA. We matched 1:1 the cS + Cx group with 45 contemporaneous patients who primarily started palliative gemcitabine-based Cx for age, sex, performance status, and body mass index. Overall, survival was evaluated.RESULTS: Local R0 and R1 resection in metastatic patients was achieved in 27% and 27%, respectively. The R2 resection status without distant metastasis resulted in 33%, whereas 13% showed a local R2 status with additional metastasis (M1). Median overall survival was 10.4 months after cytoreductive pancreatic surgery and consecutive gemcitabine-based Cx versus 7.2 months after upfront gemcitabine-based Cx (P = 0.009). Median survival for R0/M1 patients was 14.4 months and 11.0 months for R2/M0 patients, whereas the median survival for R1/M1 and for R2/M1 patients was 7.3 months and 6.1 months, respectively.CONCLUSIONS: Individual patients with advanced PA had a significantly longer overall survival after palliative pancreaticoduodenectomy followed by Cx than patients in a matched control group who underwent primarily palliative Cx.",
keywords = "Adenocarcinoma/mortality, Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic/adverse effects, Chemotherapy, Adjuvant, Cytoreduction Surgical Procedures/adverse effects, Deoxycytidine/adverse effects, Feasibility Studies, Female, Humans, Kaplan-Meier Estimate, Male, Matched-Pair Analysis, Middle Aged, Palliative Care, Pancreatectomy/adverse effects, Pancreatic Neoplasms/mortality, Pancreaticoduodenectomy/adverse effects, Proportional Hazards Models, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome",
author = "Marcus Bahra and Johann Pratschke and Fritz Klein and Peter Neuhaus and Sabine Boas-Knoop and Gero Puhl and Timm Denecke and Pullankavumkal, {Joyce R} and Marianne Sinn and Hanno Riess and Uwe Pelzer",
year = "2015",
month = aug,
doi = "10.1097/MPA.0000000000000365",
language = "English",
volume = "44",
pages = "930--6",
journal = "PANCREAS",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

RIS

TY - JOUR

T1 - Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy

AU - Bahra, Marcus

AU - Pratschke, Johann

AU - Klein, Fritz

AU - Neuhaus, Peter

AU - Boas-Knoop, Sabine

AU - Puhl, Gero

AU - Denecke, Timm

AU - Pullankavumkal, Joyce R

AU - Sinn, Marianne

AU - Riess, Hanno

AU - Pelzer, Uwe

PY - 2015/8

Y1 - 2015/8

N2 - OBJECTIVES: Pancreatoduodenectomy is feasible also in patients with locally advanced pancreatic adenocarcinoma (PA) nowadays. Data on risk and survival analysis of palliative pancreatic resections followed by gemcitabine-based chemotherapy (Cx) are limited.METHODS: Between 2000 and 2009, a total of 45 patients had primary cytoreductive surgery (cS) (pancreaticoduodenectomy or total pancreatectomy) followed by gemcitabine-based Cx (cS + Cx) for advanced PA. We matched 1:1 the cS + Cx group with 45 contemporaneous patients who primarily started palliative gemcitabine-based Cx for age, sex, performance status, and body mass index. Overall, survival was evaluated.RESULTS: Local R0 and R1 resection in metastatic patients was achieved in 27% and 27%, respectively. The R2 resection status without distant metastasis resulted in 33%, whereas 13% showed a local R2 status with additional metastasis (M1). Median overall survival was 10.4 months after cytoreductive pancreatic surgery and consecutive gemcitabine-based Cx versus 7.2 months after upfront gemcitabine-based Cx (P = 0.009). Median survival for R0/M1 patients was 14.4 months and 11.0 months for R2/M0 patients, whereas the median survival for R1/M1 and for R2/M1 patients was 7.3 months and 6.1 months, respectively.CONCLUSIONS: Individual patients with advanced PA had a significantly longer overall survival after palliative pancreaticoduodenectomy followed by Cx than patients in a matched control group who underwent primarily palliative Cx.

AB - OBJECTIVES: Pancreatoduodenectomy is feasible also in patients with locally advanced pancreatic adenocarcinoma (PA) nowadays. Data on risk and survival analysis of palliative pancreatic resections followed by gemcitabine-based chemotherapy (Cx) are limited.METHODS: Between 2000 and 2009, a total of 45 patients had primary cytoreductive surgery (cS) (pancreaticoduodenectomy or total pancreatectomy) followed by gemcitabine-based Cx (cS + Cx) for advanced PA. We matched 1:1 the cS + Cx group with 45 contemporaneous patients who primarily started palliative gemcitabine-based Cx for age, sex, performance status, and body mass index. Overall, survival was evaluated.RESULTS: Local R0 and R1 resection in metastatic patients was achieved in 27% and 27%, respectively. The R2 resection status without distant metastasis resulted in 33%, whereas 13% showed a local R2 status with additional metastasis (M1). Median overall survival was 10.4 months after cytoreductive pancreatic surgery and consecutive gemcitabine-based Cx versus 7.2 months after upfront gemcitabine-based Cx (P = 0.009). Median survival for R0/M1 patients was 14.4 months and 11.0 months for R2/M0 patients, whereas the median survival for R1/M1 and for R2/M1 patients was 7.3 months and 6.1 months, respectively.CONCLUSIONS: Individual patients with advanced PA had a significantly longer overall survival after palliative pancreaticoduodenectomy followed by Cx than patients in a matched control group who underwent primarily palliative Cx.

KW - Adenocarcinoma/mortality

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antimetabolites, Antineoplastic/adverse effects

KW - Chemotherapy, Adjuvant

KW - Cytoreduction Surgical Procedures/adverse effects

KW - Deoxycytidine/adverse effects

KW - Feasibility Studies

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Matched-Pair Analysis

KW - Middle Aged

KW - Palliative Care

KW - Pancreatectomy/adverse effects

KW - Pancreatic Neoplasms/mortality

KW - Pancreaticoduodenectomy/adverse effects

KW - Proportional Hazards Models

KW - Retrospective Studies

KW - Risk Factors

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1097/MPA.0000000000000365

DO - 10.1097/MPA.0000000000000365

M3 - SCORING: Journal article

C2 - 25931260

VL - 44

SP - 930

EP - 936

JO - PANCREAS

JF - PANCREAS

SN - 0885-3177

IS - 6

ER -